Back to top
more

Bausch Health (BHC)

(Delayed Data from NYSE)

$8.48 USD

8.48
1,027,632

-0.28 (-3.20%)

Updated Nov 15, 2024 04:00 PM ET

After-Market: $8.48 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Generic Drugs

Zacks News

Bausch Health (BHC) Gains As Market Dips: What You Should Know

In the latest trading session, Bausch Health (BHC) closed at $25.06, marking a +0.56% move from the previous day.

Anthem (ANTM) Gears Up for Q4 Earnings: What's in the Cards?

Anthem's (ANTM) fourth-quarter results are likely to reflect gains from increased premiums and strong membership growth across its Medicare and Medicaid businesses, partly offset by rising expenses.

UnitedHealth (UNH) Q4 Earnings Beat Estimates, Improve Y/Y

UnitedHealth's (UNH) Q4 results reflect higher revenues, driven by segmental contributions, partly offset by steep expenses.

Bausch (BHC) Eye Care Business Files for IPO in the US & Canada

Bausch (BHC) eye care business files for an initial public offering in the United States and Canada.

Bausch Health (BHC) Stock Sinks As Market Gains: What You Should Know

Bausch Health (BHC) closed the most recent trading day at $27.34, moving -1.51% from the previous trading session.

Bausch Health (BHC) Outpaces Stock Market Gains: What You Should Know

Bausch Health (BHC) closed the most recent trading day at $27.79, moving +0.65% from the previous trading session.

Why Is Bausch (BHC) Down 15.6% Since Last Earnings Report?

Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Bausch's (BHC) Q3 Earnings Beat Estimates, Revenues Miss

Bausch (BHC) beats on earnings but misses on sales in the third quarter. The company reiterates annual revenue guidance.

Bausch Health (BHC) Beats Q3 Earnings Estimates

Bausch (BHC) delivered earnings and revenue surprises of 6.54% and -1.95%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Earnings Preview: Bausch Health (BHC) Q3 Earnings Expected to Decline

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Anthem's (ANTM) Q3 Earnings Beat Estimates, Increase Y/Y

Anthem's (ANTM) third-quarter results reflect higher revenues and solid contribution from its segments.

What's in Store for HCA Healthcare's (HCA) Q3 Earnings?

HCA Healthcare's (HCA) Q3 results are likely to reflect better revenues owing to higher patient volumes.

Bausch's (BHC) NOV03 for Dry Eye Disease Meets Study Goal

Bausch Health (BHC) achieves study endpoints in the phase III study evaluating its investigational drug NOV03 in patients with DED associated with MGD.

Bausch Health (BHC) is a Top-Ranked Value Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Bausch (BHC) Surges 8%: Is This an Indication of Further Gains?

Bausch (BHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

AptarGroup (ATR) Buys Stake in Voluntis, Boosts Capabilities

AptarGroup (ATR) completes the acquisition of 64.6% stake in Voluntis, which will help expand its digital healthcare offerings and drive innovation in the healthcare space.

Why Is Bausch (BHC) Up 15.2% Since Last Earnings Report?

Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

3 Generic Drug Stocks to Watch Amid Pandemic & Pricing Pressure

The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in the second half of 2021. Moreover, stable pricing and improving demand in some countries in 2021 may bode well for RDY, BHC and AMPH.

Bausch's (BHC) Q2 Earnings Beat Estimates, Revenues Miss

Bausch (BHC) beats on earnings but misses on sales in the second quarter. The company also lowers its annual revenue guidance.

Bausch Health (BHC) Tops Q2 Earnings Estimates

Bausch (BHC) delivered earnings and revenue surprises of 1.03% and -0.97%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Why Bausch (BHC) Might Surprise This Earnings Season

Bausch (BHC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Ekta Bagri headshot

4 Pharma/Biotech Stocks Poised to Beat on Earnings in Q2

We take a look at a few pharma/biotech companies, which are poised to beat on earnings in the second quarter.

Why Bausch (BHC) is Poised to Beat Earnings Estimates Again

Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Bausch Health (BHC) Earnings Expected to Grow: Should You Buy?

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.